Missing Script

Get updates

Evidence Explorer / MS-N199 / Supportive physical care / Appraised November 1, 2026

Cooling and pressure are both being tested to reduce chemotherapy-induced peripheral neuropathy (CIPN). The key comparative trial found no advantage for cryocompression over cryotherapy—and because it lacked an untreated control, it cannot show that either strategy worked better than usual care.

Evidence at a glance

  • Population: 200 people receiving taxane chemotherapy for breast or gynecologic cancers.
  • Design: randomized comparison of upper-extremity cryotherapy with cryocompression; no usual-care or sham group.
  • Finding: grade 1 CIPN occurred in 30.1% with cryotherapy and 32.8% with cryocompression; grade 2 or worse CIPN occurred in 13.7% and 17.2%, respectively.
  • Evidence label: comparative evidence; no superiority shown.
  • Clinical boundary: prevention of treatment toxicity only—not cancer control.

What was studied

The Cropsi randomized trial recruited 200 participants and applied either cryotherapy or cryocompression to the upper extremities during taxane treatment. The PubMed record reports no significant differences in neurologic assessments or quality of life. Cryocompression did not outperform cryotherapy.

The absolute event rates are useful for planning future trials, but they should not be read as proof of benefit. Without a concurrent untreated or sham group, the study cannot separate an intervention effect from the underlying neuropathy rate, dose changes, drug choice, assessment method or patient selection.

Hilotherm provided financial and administrative support, and the publication discloses an author relationship involving Hilotherm grant funding. That does not invalidate the trial, but it is relevant when interpreting a device comparison.

What this evidence cannot establish

The comparison answers a narrow question: whether this cryocompression protocol was better than this cryotherapy protocol. It does not establish that either should become routine care.

The trial mixed taxanes and cancer populations, and the abstract does not provide complete analyzed denominators for every endpoint, adherence details or confidence intervals. Those fields remain not verified here.

Practical safety context

Both cold and compression can be uncomfortable. Extra caution is sensible with Raynaud disease, peripheral vascular disease, impaired sensation, broken skin or inability to report pain. Devices should be applied and monitored under a standardized clinic protocol.

Remove the device and ask for assessment if there is severe pain, persistent color change, burning, blistering or worsening numbness.

Questions for the care team

  • Which drug, device pressure, temperature and treatment window does your protocol use?
  • How will my skin, circulation and comfort be checked?
  • What neuropathy scale will the team use, and when would chemotherapy dosing be reconsidered?

Sources

Source note: Full text and PubMed metadata were checked. The report is one randomized comparison, not two independent efficacy trials. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.

This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.